

Antonio Solana-Altabella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6608678/publications.pdf>

Version: 2024-02-01

14
papers

80
citations

1937457

4
h-index

1588896

8
g-index

14
all docs

14
docs citations

14
times ranked

68
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1989-2007.	0.8	26
2	Computer vision-based analytical chemistry applied to determining iron in commercial pharmaceutical formulations. <i>Talanta</i> , 2018, 188, 349-355.	2.9	12
3	Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 659-668.	0.6	10
4	Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 1-18.	1.0	7
5	Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. <i>Expert Review of Hematology</i> , 2020, 13, 1057-1065.	1.0	5
6	Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1829-1835.	0.5	5
7	Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia. <i>Pharmaceutics</i> , 2022, 14, 878.	2.0	5
8	Developing a telepharmacy programme with home medication dispensing and informed delivery in a tertiary hospital: description of the model and analysis of the results. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 107-112.	0.5	4
9	Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia. <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 133-139.	0.7	2
10	Extracorporeal photopheresis vs standard therapies for steroidâ€refractory chronic graftâ€vsâ€host disease: Pharmacoeconomic assessment of hospital resource use in Spain. <i>Journal of Clinical Apheresis</i> , 2021, 36, 612-620.	0.7	2
11	Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. <i>European Journal of Haematology</i> , 2021, 106, 724-733.	1.1	1
12	Healthcare Resource Utilization among Patients between 60â€75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study. <i>Cancers</i> , 2022, 14, 1921.	1.7	1
13	Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. <i>Future Oncology</i> , 2021, 17, 215-227.	1.1	0
14	Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 2727-2736.	0.6	0